Used in the treatment of certain B-cell malignancies, particularly relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia. It functions as a dual inhibitor of PI3K-delta and casein kinase-1-epsilon, helping to block signaling pathways that promote tumor growth and survival. Its selectivity may reduce immune-related toxicities compared to other inhibitors, making it a valuable option in patients who have failed prior therapies. Currently under investigation in clinical trials to expand its use in combination regimens and other hematologic cancers.